Permanent radiotherapy implants reduce risk of prostate cancer recurrence after 5 years

(European Society for Radiotherapy and Oncology (ESTRO)) Results from a randomized controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later. The research will be presented at the 3rd ESTRO Forum in Barcelona, Spain,